MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.jaccao.2022.07.011

Медицинская библиотека · JACC. CardioOncology · 2022

Prevalence, Treatment, and Prognosis of Tumor Thrombi in Renal Cell Carcinoma.

Kaptein Fleur H J, van der Hulle Tom, Braken Sander J E, van Gennep Erik J, Buijs Jeroen T, Burgmans Mark C, Cannegieter Suzanne C, du Chatinier Emma M E, Huisman Menno V, van Persijn van Meerten Els L, Versteeg Henri H, Pelger Rob C M, Klok Frederikus A

СтатьяПеревод в очереди

Аннотация

BACKGROUND

Renal cell carcinoma (RCC) can be complicated by a venous tumor thrombus (TT), of which the optimal management is unknown.

OBJECTIVES

This study sought to assess the prevalence of TT in RCC, its current management, and its association with venous thromboembolism (VTE), arterial thromboembolism (ATE), major bleeding (MB), and mortality.

METHODS

Patients diagnosed with RCC between 2010 and 2019 in our hospital were included and followed from RCC diagnosis until 2 years after, or until an outcome of interest (VTE, ATE, and MB) or death occurred, depending on the analysis. Cumulative incidences were estimated with death as a competing risk. Cause-specific hazard models were used to identify predictors and the prognostic impact.

RESULTS

Of the 647 patients, 86 had a TT (prevalence 13.3%) at RCC diagnosis, of which 34 were limited to the renal vein, 37 were limited to the inferior vena cava below the diaphragm, and 15 extended above the diaphragm; 20 patients started therapeutic anticoagulation and 45 underwent thrombectomy with/without anticoagulation. During follow-up (median 24.0 [IQR: 7.0-24.0] months), 17 TT patients developed a VTE, 0 developed an ATE, and 11 developed MB. TT patients were more often diagnosed with VTE (adjusted HR: 6.61; 95% CI: 3.18-13.73) than non-TT patients, with increasing VTE risks in more proximal TT levels. TT patients receiving anticoagulation still developed VTE (HR: 0.56; 95% CI: 0.13-2.48), at the cost of more MB events (HR: 3.44; 95% CI: 0.95-12.42) compared with those without anticoagulation.

CONCLUSIONS

Patients with RCC-associated TT were at high risk of developing VTE. Future studies should establish which of these patients benefit from anticoagulation therapy.

Для цитирования: Kaptein Fleur H J, van der Hulle Tom, Braken Sander J E, van Gennep Erik J, Buijs Jeroen T, Burgmans Mark C, Cannegieter Suzanne C, du Chatinier Emma M E, Huisman Menno V, van Persijn van Meerten Els L, Versteeg Henri H, Pelger Rob C M, Klok Frederikus A. Prevalence, Treatment, and Prognosis of Tumor Thrombi in Renal Cell Carcinoma.. JACC. CardioOncology. 2022. DOI: 10.1016/j.jaccao.2022.07.011.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.